Century Therapeutics SVP auto-sells shares for taxes

Century Therapeutics SVP Finance & Operations Douglas Carr reported an automatic sale of common stock tied to tax withholding on vested restricted stock units.

Rhea-AI Filing Summary

Century Therapeutics SVP Finance & Operations Douglas Carr reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On March 9, 2026, he sold 247 shares at $2.536 per share to cover tax obligations. After this transaction, he continued to hold 514,304 shares of Century Therapeutics common stock directly. The footnote explains these sales were required and not at his discretion, indicating a routine tax-related transaction rather than an active portfolio decision.

Insider Trade Summary

Net Seller: 247 shares

Net Sell 1 txn

Insider Carr Douglas

Role SVP Finance & Operations

Sold 247 shs ($626.39)

Type	Security	Shares	Price	Value
Sale	Common Stock	247	$2.536	$626.39

Holdings After Transaction: Common Stock — 514,304 shares (Direct)

Footnotes (1)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Century Therapeutics (IPSC) executive Douglas Carr report on this Form 4?

Douglas Carr reported an automatic sale of 247 Century Therapeutics shares to cover tax withholding on vested restricted stock units. The transaction reflects routine tax management, not a discretionary change in his investment position in the company.

How many Century Therapeutics (IPSC) shares did Douglas Carr sell and at what price?

Douglas Carr sold 247 shares of Century Therapeutics common stock at $2.536 per share. According to the filing, this sale was executed solely to satisfy tax withholding obligations related to restricted stock unit vesting.

How many Century Therapeutics (IPSC) shares does Douglas Carr hold after the reported transaction?

Following the tax-related sale, Douglas Carr holds 514,304 shares of Century Therapeutics common stock directly. This shows the transaction affected only a very small portion of his overall position in the company’s equity.

Was Douglas Carr’s sale of IPSC shares a discretionary trade?

No. The footnote explains the 247-share sale was required to cover tax withholding on restricted stock unit vesting and was automatic. The filing states the sale was not at the discretion of Douglas Carr, indicating a routine administrative transaction.

What is the nature of the restricted stock unit vesting mentioned for Century Therapeutics (IPSC)?

The filing notes that restricted stock units held by Douglas Carr vested, triggering tax obligations. To satisfy these obligations, 247 shares were automatically sold, with proceeds used for withholding taxes rather than representing a voluntary reduction in his ownership stake.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Douglas

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Finance & Operations

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		247	D	$2.536	514,304	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Douglas Carr	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.